Patients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatment
Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics
Patients should not have any clinical evidence of an active infection at the time of enrollment
Patients with a previous or current line infection are ineligible until 14 days after the completion of antibiotics
Clinically active infection; an active infection may alter the biodistribution of 18F-FLT
Patients must not have a systemic bacterial, fungal, or viral infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)
Active bacterial or fungal infection; all prior infections must be resolved following optimal therapy
Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 14 days prior to randomization
Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before Segment B enrollment
Active lung infection
Concurrent, acute, active infection, or treatment for infection, other than oral thrush or genital herpes, within 14 days of enrollment
Active infection or chronic infection requiring chronic suppressive antibiotics
Opportunistic infection within the last 3 months
Ongoing or active infection; treatment with systemic antibiotics or antifungals for ongoing or recurrent infection (topical use of antibiotics or antifungals is allowed)
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
Active infection
Patients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibiotics
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
Patients who have an active uncontrolled infection defined as: * Positive bacterial blood culture within 48 hours of study enrollment; * Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability* A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection* Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved; for patients with clostridium (c.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline* Active viral or protozoal infection requiring IV treatment